Compare Abbott Laboratories (ABT) vs Allstate Corp (ALL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Allstate Corp — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Allstate Corp trades at $252.25 (market cap $63.94B). The key difference: Abbott Laboratories is far larger — about 2.6× Allstate Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | ALL | |
|---|---|---|
Market Cap | $166.94B | $63.94B |
Sector | Health | Financials |
52-Week High | $136.62 | $251.46 |
52-Week Low | $82.57 | $190.00 |
Enterprise Value | $193.69B | $72.73B |
Dividend Yield | 2.63% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Allstate (ALL) trades at $251.46, up 0.45% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 5.49, net income margin of 17.98%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 earnings anticipation and dividend declarations, reinforcing positive sentiment.
Outlook remains favorable given valuation discounts and earnings strength, though risks include potential hurricane impacts and market volatility. Analyst consensus leans bullish with a $249.50 price target, suggesting near-term stability with upside potential from continued operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →
